Deutsche Bank maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $17. The stock declined ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE